{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang G"],"funding":["National Cancer Institute","NCI NIH HHS"],"pagination":["301.e17-301.e28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8501538"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(5)"],"pubmed_abstract":["Purpose
We evaluated the prognostic value of 10 putative tumor markers by immunohistochemistry in a large multi-institutional cohort of patients with locally advanced urothelial cancer of the bladder (UCB) with the aim to validate their clinical value and to harmonize protocols for their evaluation.Materials and methods
Primary tumor specimens from 576 patients with pathologic (p)T3 UCB were collected from 24 institutions in North America and Europe. Three replicate 0.6-mm core diameter samples were collected for the construction of a tissue microarray (TMA). Immunohistochemistry (IHC) for 10 previously described tumor markers was performed and scored at 3 laboratories independently according to a standardized protocol. Associations between marker positivity and freedom fro"],"journal":["Urologic oncology"],"pubmed_title":["Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project."],"pmcid":["PMC8501538"],"funding_grant_id":["P30 CA016672","P50 CA091846","R01 CA071921"],"pubmed_authors":["Dinney CP","Minner S","Cote RJ","Ji L","Wang G","Black PC","Cordon-Cardo C","Groshen S","Schmitz-Drager B","Hawes D","Sauter G","Czerniak B","Waldman F","Goebell PJ"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.","description":"Purpose
We evaluated the prognostic value of 10 putative tumor markers by immunohistochemistry in a large multi-institutional cohort of patients with locally advanced urothelial cancer of the bladder (UCB) with the aim to validate their clinical value and to harmonize protocols for their evaluation.Materials and methods
Primary tumor specimens from 576 patients with pathologic (p)T3 UCB were collected from 24 institutions in North America and Europe. Three replicate 0.6-mm core diameter samples were collected for the construction of a tissue microarray (TMA). Immunohistochemistry (IHC) for 10 previously described tumor markers was performed and scored at 3 laboratories independently according to a standardized protocol. Associations between marker positivity and freedom fro","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-05T14:05:32.235Z","creation":"2025-04-05T14:05:32.235Z"},"accession":"S-EPMC8501538","cross_references":{"pubmed":["33563539"],"doi":["10.1016/j.urolonc.2021.01.021"]}}